The Food and Drug Administration said it will allow some pancreatic cancer patients to receive access to a promising drug, even before it is officially approved for use. The medication, daraxonrasib, is a 300 milligram pill taken once a day. The drug blocks a signal that causes cancer cells to
The Food and Drug Administration said it will allow some pancreatic cancer patients to receive access to a promising drug, even before it is officially approved for use. The medication, daraxonrasib, is a 300 milligram pill taken once a day. The drug blocks a signal that causes cancer cells to grow non-stop. Drugmaker Revolution Medicine reported that in a clinical trial, metastatic pancreatic cancer patients who took the drug survived a median of 13 months, compared to about six months for similar patients who underwent chemotherapy. Former Sen. Ben Sasse, 54, called daraxonrasib “a miracle drug” in a conversation with “60 Minutes” and said it has helped him live longer and with less pain. He was diagnosed with stage-four pancreatic cancer in December. “I have much, much less pain than I had four
